Literature DB >> 6402127

Failure of renal dopamine response to salt loading in chronic renal disease.

I F Casson, M R Lee, A M Brownjohn, F M Parsons, A M Davison, E J Will, A D Clayden.   

Abstract

Eight patients with chronic glomerulonephritis and five age-matched normal volunteers were given additional sodium chloride by mouth under conditions of metabolic balance. Whereas in the normal volunteers plasma renin activity was suppressed and urinary excretion of free dopamine increased, in the patients dopamine was not mobilised and plasma renin activity was not completely suppressed. Abnormal retention of sodium and water in glomerulonephritis may be due partly to a failure to mobilise dopamine in the kidney. Specific renal dopamine agonists may be natriuretic and hypotensive in chronic glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402127      PMCID: PMC1546573          DOI: 10.1136/bmj.286.6364.503

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  20 in total

Review 1.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

2.  Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system.

Authors:  M A Schalekamp; D G Beevers; J D Briggs; J J Brown; D L Davies; R Fraser; M Lebel; A F Lever; A Medina; J J Morton; J I Robertson; M Tree
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension.

Authors:  A C Guyton; T G Coleman; A V Cowley; K W Scheel; R D Manning; R A Norman
Journal:  Am J Med       Date:  1972-05       Impact factor: 4.965

Review 4.  Hypertension and chronic renal failure.

Authors:  J J Brown; G Düsterdieck; R Fraser; A F Lever; J I Robertson; M Tree; R J Weir
Journal:  Br Med Bull       Date:  1971-05       Impact factor: 4.291

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure.

Authors:  D L Davies; D G Beevers; J D Briggs; A M Medina; J I Robertson; M A Schalekamp; J J Brown; A F Lever; J J Morton; M Tree
Journal:  Lancet       Date:  1973-03-31       Impact factor: 79.321

7.  Renin secretion in renal hypertension.

Authors:  D J Warren; T F Ferris
Journal:  Lancet       Date:  1970-01-24       Impact factor: 79.321

8.  Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa.

Authors:  G D Finlay; T L Whitsett; E A Cucinell; L I Goldberg
Journal:  N Engl J Med       Date:  1971-04-15       Impact factor: 91.245

9.  Muscle biopsy water and electrolyte contents in chronic renal failure.

Authors:  J A Graham; D H Lawson; A L Linton
Journal:  Clin Sci       Date:  1970-05       Impact factor: 6.124

10.  Hypertension in end-stage renal disease.

Authors:  V Vertes; J L Cangiano; L B Berman; A Gould
Journal:  N Engl J Med       Date:  1969-05-01       Impact factor: 91.245

View more
  3 in total

1.  Lack of effect of ibopamine, a dopamine pro-drug, on renal function in normal subjects.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

2.  Atrial natriuretic peptide and sodium homeostasis in chronic renal failure.

Authors:  T Tulassay; W Rascher; K Schärer
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

3.  The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.